<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04869553</url>
  </required_header>
  <id_info>
    <org_study_id>RC-P00102</org_study_id>
    <nct_id>NCT04869553</nct_id>
  </id_info>
  <brief_title>Analgesic Efficacy of Hypnosis and Virtual Reality in Repetitive Pain Care</brief_title>
  <acronym>PADIS</acronym>
  <official_title>Analgesic Efficacy of Hypnosis and Virtual Reality in Repetitive Pain Care : a Controlled, Randomised, Cross-over, Open-label, Multi-centre Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lille Catholic University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lille Catholic University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The originality of this study is the comparison of different distractibility techniques&#xD;
      (hypnosis and virtual reality) in the very heterogenous contexts of pain management. This&#xD;
      study will consider all types of care situations. The study's cross-over design will take&#xD;
      into account this heterogenous context. The results will be representative of real-life&#xD;
      situations where care for pain involves a wide range of contexts.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pain is defined as an unpleasant sensorial and emotional experience related to a potential or&#xD;
      existing tissue injury (psychological (affective) and physical dimension of pain). Since it&#xD;
      can occur at any stage of care, pain concerns all healthcare teams working in acute care&#xD;
      units or follow-up care centers.&#xD;
&#xD;
      At the present time, pain management is mainly based on the use of analgesic agents that calm&#xD;
      or suppress pain. Different types of analgesic agents are available in the therapeutic&#xD;
      armamentarium (non-opioid analgesics and opioid analgesics as morphine).&#xD;
&#xD;
      In this context where pain management is a priority and where the use of morphine is&#xD;
      constantly on the rise exposing patients to significant risk (adverse effects, addictions,&#xD;
      respiratory events….), the use of distractibility techniques as hypnosis and virtual reality&#xD;
      could be an attractive alternative.&#xD;
&#xD;
        -  Hypnosis designates both a therapeutic technique and a modified state of consciousness&#xD;
           also called trance (a state where the person is between a state of wakefulness and&#xD;
           sleep).&#xD;
&#xD;
        -  Virtual reality designates a three-dimensional computer-controlled environment allowing&#xD;
           immersion, interaction and multisensorial input.&#xD;
&#xD;
      Thus, the originality of this study is the comparison of different distractibility techniques&#xD;
      in the very heterogenous contexts of pain management. This study will consider all types of&#xD;
      care situations. The study's cross-over design will take into account this heterogenous&#xD;
      context. The results will be representative of real-life situations where care for pain&#xD;
      involves a wide range of contexts.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 30, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Controlled, randomised, open-label, cross-over, 3-sequence study (uniform design across time and sequence: ABC/BCA/CAB).&#xD;
Treatment A: Usual pain management of each ward&#xD;
Treatment B: Usual pain management on each ward and analgesic hypnotherapy during care&#xD;
Treatment C: Usual pain management of each ward and virtual reality session using a suitable headset.</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Analgesia Nociception Index (ANI) during painful care interventions</measure>
    <time_frame>one month</time_frame>
    <description>This index is derived from heart rate variability and reflects the relative parasympathetic tone. An ANI value close to 100 corresponds to a prominent parasympathetic tone (low stress level, analgesia) and a value close to 0 corresponds to a prominent sympathetic tone (high stress level, nociception).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ANI's average score (Analgesia Nociception Index) 5 minutes after the care and the distractibility methods</measure>
    <time_frame>one month</time_frame>
    <description>A comparison between the ANI's score before and after the care and the distractibility methods. The average of the scores will be retained.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale (VAS)</measure>
    <time_frame>one month</time_frame>
    <description>The pain's level will be evaluated by the Visual Analog Scale (VAS). This scale measure the pain's intensity from 0 to 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morphine equivalent</measure>
    <time_frame>one month</time_frame>
    <description>The opioid analgesics administered during the care will be converted into morphine equivalent by means of the opioid equi-analgesia table. The collection of analgesics will include all analgesics &quot;in action&quot; on the day of care.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients tolerance to distractibility techniques</measure>
    <time_frame>one month</time_frame>
    <description>All events leading to a discontinuation of the distractibility technique will be recorded: side effects /cybersickness (nausea, vertigo evaluated using the Speech, Spatial and Qualities (SSQ) of Hearing Scale prolonged procedure, dissociative disorders …), patient refusal, care-related elements preventing the use of the distractibility technique or leading to premature discontinuation of its use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between patient age and tolerance</measure>
    <time_frame>one month</time_frame>
    <description>The impact of age on abandon (irrespective of the reason) will be noted to search for a link between age and tolerance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between patient age and treatment efficacy</measure>
    <time_frame>one months</time_frame>
    <description>The impact of age on treatment effect on ANI score during the care procedure will be noted to search for a link between age and treatment efficacy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between caregiver training level and hypnosis efficacy</measure>
    <time_frame>one month</time_frame>
    <description>Hypnosis training level will be determined by the duration of training (hours) and the professional level (1/2/3). Caregiver category (nurse/psychologist/rehabilitation specialist…) and the number of hypno-therapy sessions delivered during the six months preceding the study will also be considered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of satisfaction concerning the distractibility techniques.</measure>
    <time_frame>one month</time_frame>
    <description>A questionnaire will evaluate patient perceptions concerning the distractibility techniques.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IPQ (Igroup Presence Questionnaire) scale</measure>
    <time_frame>one month</time_frame>
    <description>The IPQ is a 14-item self-administered questionnaire. This scale is used to measure the patient's feelings about spatial presence, the implication and sense of the reality perceived in the virtual reality.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>ABC's arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The 3 pain managements are in the ABC's order.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCA's arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The 3 pain managements are in the BCA's order.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CAB's arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The 3 pain managements are in the CAB's order.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Management pain with distraction methods ABC</intervention_name>
    <description>Every patient will receive :&#xD;
The usual pain management of their ward (Treatment A),&#xD;
The usual pain management of their ward with a hypnosis session (Treatment B)&#xD;
The usual pain management of their ward with a virtual reality session (Treatment C)</description>
    <arm_group_label>ABC's arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Management pain with distraction methods BCA</intervention_name>
    <description>Every patient will receive :&#xD;
The usual pain management of their ward with a hypnosis session (Treatment B)&#xD;
The usual pain management of their ward with a virtual reality session (Treatment C)&#xD;
The usual pain management of their ward (Treatment A)</description>
    <arm_group_label>BCA's arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Management pain with distraction methods CAB</intervention_name>
    <description>Every patient will receive :&#xD;
The usual pain management of their ward with a virtual reality session (Treatment C)&#xD;
The usual pain management of their ward (Treatment A)&#xD;
The usual pain management of their ward with a hypnosis session (Treatment B)</description>
    <arm_group_label>CAB's arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing care interventions of a given type (e.g. wound&#xD;
             dressings/mobilization/…) recognized as painful (pain VAS &gt;3 despite the usual&#xD;
             analgesic protocol)&#xD;
&#xD;
          -  Repetition of the same type of intervention at least three times within a month of&#xD;
             interval after inclusion&#xD;
&#xD;
          -  Patient age ≥15 years&#xD;
&#xD;
          -  Informed consent from patient or legal guardian&#xD;
&#xD;
          -  Beneficiary of the French healthcare fund&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cognitive or psychiatric disorders preventing the patient from communicating with&#xD;
             caregivers or understanding their instructions&#xD;
&#xD;
          -  Any other concomitant nervous system, cardiac, or pulmonary disease that might affect&#xD;
             the autonomous nervous system: (myocardial infarction, myocardial disorder (e.g.&#xD;
             dilated or hypertrophic cardiomyopathy), class 3 or 4 heart failure, cardia&#xD;
             dysrhythmia, including atrial fibrillation, conduction disorder, mechanical&#xD;
             ventilation)&#xD;
&#xD;
          -  Non-sinusal rhythm, extrasystoles, altered ECG signals&#xD;
&#xD;
          -  Mandatory drug therapy that might affect the autonomous nervous system and NRV such as&#xD;
             beta-blockers, muscarinic receptor blockers, vasopressin agents&#xD;
&#xD;
          -  Contraindication for use of the virtual reality headset and/or hypnosis. Neurological&#xD;
             disorder incompatible with use of the virtual reality headset and/or hypnosis (balance&#xD;
             disorders/seizures…)&#xD;
&#xD;
          -  Contraindication for using surface electrodes preventing collection of the main&#xD;
             endpoint data&#xD;
&#xD;
          -  Any disorder or disability preventing execution of the virtual reality or hypnosis&#xD;
             techniques (deafness/blindness)&#xD;
&#xD;
          -  Judicial protection status&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie-Noëlle BARTHOLOMEI, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>Hôpital Léon Bérard</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amélie Lansiaux, MD, PhD</last_name>
    <phone>03 20 22 52 69</phone>
    <email>Lansiaux.Amelie@ghicl.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mélody Plets, MSc</last_name>
    <phone>03 20 22 57 33</phone>
    <email>Plets.Melody@ghicl.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Léon Bérard</name>
      <address>
        <city>Hyères</city>
        <zip>83418</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Noëlle BARTHOLOMEI, PharmD</last_name>
      <email>mn.bartholomei@leonberard.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre médico-chirurgical des Massues</name>
      <address>
        <city>Lyon</city>
        <zip>69322</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emmanuelle CHALEAT- VALAYER, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>USSAP - Centre Bouffard Vercelli</name>
      <address>
        <city>Perpignan</city>
        <zip>66962</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Charles FATTAL, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Mutualiste de Kerpape</name>
      <address>
        <city>Ploemeur</city>
        <zip>56275</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacques KERDRAON, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pôle MPR Saint Hélier</name>
      <address>
        <city>Rennes</city>
        <zip>35043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jephté HOUEDAKOR, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondation ILDYS - Site de Perharidy</name>
      <address>
        <city>Roscoff</city>
        <zip>29684</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrée Marie SALAUN, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondation Ellen Poidatz - Centre de Rééducation Fonctionnelle</name>
      <address>
        <city>Saint-Fargeau-Ponthierry</city>
        <zip>77210</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rossana SPIRITO, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>SSR Pédiatrique Marc Sautelet</name>
      <address>
        <city>Villeneuve-d'Ascq</city>
        <zip>59653</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Valérie HUE, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 28, 2021</study_first_submitted>
  <study_first_submitted_qc>April 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2021</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pain management</keyword>
  <keyword>Hypnosis</keyword>
  <keyword>Virtual Reality</keyword>
  <keyword>Distractibility methods</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

